CollPlant Biotechnologies (CLGN) Competitors $2.03 +0.21 (+11.45%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.94 -0.09 (-4.43%) As of 07/18/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLGN vs. NVNO, NSPR, CTSO, MDAI, SURG, HYPR, EDAP, ICCM, MLSS, and APTShould you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include enVVeno Medical (NVNO), InspireMD (NSPR), Cytosorbents (CTSO), Spectral AI (MDAI), SurgePays (SURG), Hyperfine (HYPR), Edap Tms (EDAP), IceCure Medical (ICCM), Milestone Scientific (MLSS), and Alpha Pro Tech (APT). These companies are all part of the "medical equipment" industry. CollPlant Biotechnologies vs. Its Competitors enVVeno Medical InspireMD Cytosorbents Spectral AI SurgePays Hyperfine Edap Tms IceCure Medical Milestone Scientific Alpha Pro Tech CollPlant Biotechnologies (NASDAQ:CLGN) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Do insiders and institutionals hold more shares of CLGN or NVNO? 21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 16.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer CLGN or NVNO? In the previous week, CollPlant Biotechnologies had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 0 mentions for enVVeno Medical. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled enVVeno Medical'saverage media sentiment score. Company Overall Sentiment CollPlant Biotechnologies Neutral enVVeno Medical Neutral Do analysts rate CLGN or NVNO? CollPlant Biotechnologies presently has a consensus price target of $11.50, suggesting a potential upside of 466.50%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe CollPlant Biotechnologies is more favorable than enVVeno Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CollPlant Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33enVVeno Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CLGN or NVNO more profitable? enVVeno Medical has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -560.92%. enVVeno Medical's return on equity of -51.32% beat CollPlant Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets CollPlant Biotechnologies-560.92% -87.33% -65.31% enVVeno Medical N/A -51.32%-48.23% Which has more risk and volatility, CLGN or NVNO? CollPlant Biotechnologies has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Which has higher valuation and earnings, CLGN or NVNO? CollPlant Biotechnologies has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollPlant Biotechnologies$510K50.63-$16.61M-$1.22-1.66enVVeno MedicalN/AN/A-$21.82M-$1.18-4.21 SummaryCollPlant Biotechnologies beats enVVeno Medical on 9 of the 15 factors compared between the two stocks. Get CollPlant Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLGN vs. The Competition Export to ExcelMetricCollPlant BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.16M$2.95B$5.55B$9.40BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-1.6619.7528.0119.82Price / Sales50.63300.24432.8198.20Price / CashN/A42.5936.1658.27Price / Book1.727.678.125.65Net Income-$16.61M-$55.28M$3.25B$257.91M7 Day Performance40.97%4.85%1.68%3.38%1 Month Performance35.33%11.70%7.30%11.11%1 Year Performance-58.66%3.69%32.89%18.99% CollPlant Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLGNCollPlant Biotechnologies1.816 of 5 stars$2.03+11.5%$11.50+466.5%-59.1%$23.16M$510K-1.6670Gap UpHigh Trading VolumeNVNOenVVeno Medical0.5091 of 5 stars$3.93-1.5%N/A-13.7%$69.97MN/A-3.3330NSPRInspireMD2.9069 of 5 stars$2.22-0.9%$4.50+102.7%-0.4%$68.62M$7.03M-2.9650High Trading VolumeCTSOCytosorbents1.7572 of 5 stars$1.03-5.5%$5.50+434.0%-1.0%$68.25M$35.33M-3.68220Gap UpMDAISpectral AI3.5615 of 5 stars$2.72+1.5%$4.75+74.6%+42.6%$67.85M$29.58M-5.0483SURGSurgePays3.0368 of 5 stars$3.30+1.9%$9.00+172.7%-3.6%$66.14M$40.03M-1.1840HYPRHyperfine1.6719 of 5 stars$0.77-4.4%$1.06+38.6%-25.8%$62.27M$12.89M-1.42190News CoverageEDAPEdap Tms2.3162 of 5 stars$1.57-1.3%$8.50+441.4%-69.4%$59.45M$69.18M-2.53230Gap DownICCMIceCure Medical2.1533 of 5 stars$1.05-0.5%$2.50+138.1%+34.2%$58.56M$3.27M-3.7560Gap DownMLSSMilestone Scientific3.1226 of 5 stars$0.68+1.5%$1.25+83.8%-28.3%$52.58M$8.61M-9.7130News CoverageNegative NewsAPTAlpha Pro Tech1.1352 of 5 stars$4.78+0.6%N/A-18.8%$51.93M$58.18M12.92120News Coverage Related Companies and Tools Related Companies enVVeno Medical Competitors InspireMD Competitors Cytosorbents Competitors Spectral AI Competitors SurgePays Competitors Hyperfine Competitors Edap Tms Competitors IceCure Medical Competitors Milestone Scientific Competitors Alpha Pro Tech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLGN) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
